Marco Denina

Dr. Marco Denina

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Pediatrics
Verified
Journal Article
Open access
PDF file
MDMarco Denina
Marco Denina
CSCarlo Scolfaro
Carlo Scolfaro
ESErika Silvestro
Erika Silvestro
GPGiulia Pruccoli
Giulia Pruccoli
FMFederica Mignone
Federica Mignone
SGSilvia Garazzino
Silvia Garazzino

1 February 2021 in Talanta
Verified
Journal Article
Closed access
Simone CavaleraSimone Cavalera
Simone Cavalera
BCBarbara Colitti
Barbara Colitti
SRSergio Rosati
Sergio Rosati
GFGianmarco Ferrara
Gianmarco Ferrara
LBLuigi Bertolotti
Luigi Bertolotti
Department ChemistryDepartment Chemistry
Department Chemistry

29 September 2020 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
MDMarco Denina
Marco Denina
GPGiulia Pruccoli
Giulia Pruccoli
CSCarlo Scolfaro
Carlo Scolfaro
FMFederica Mignone
Federica Mignone
MZMarisa Zoppo
Marisa Zoppo
SGSilvia Garazzino
Silvia Garazzino
Little is known about the sequelae of SARS-CoV-2 infection in children. In a COVID-19 dedicated clinic, we followed-up for 4 months 25 children previously hospitalized for COVID-19, performing clinical, laboratory, and lung ultrasound evaluation. Mid-term sequelae were rarely observed in our COVID-19 children’s cohort.

Verified
Journal Article
Open access
PDF file
PTPier-Angelo Tovo
Pier-Angelo Tovo
SGSilvia Garazzino
Silvia Garazzino
VDValentina Daprà
Valentina Daprà
GPGiulia Pruccoli
Giulia Pruccoli
CCCristina Calvi
Cristina Calvi
MBMassimiliano Bergallo
Massimiliano Bergallo
Children with the new coronavirus disease 2019 (COVID-19) have milder symptoms and a better prognosis than adult patients. Several investigations assessed type I, II, and III interferon (IFN) signatures in SARS-CoV-2 infected adults, however no data are available for pediatric patients. TRIM28 and SETDB1 regulate the transcription of multiple genes involved in the immune response as well as of human endogenous retroviruses (HERVs). Exogenous viral infections can trigger the activation of HERVs, which in turn can induce inflammatory and immune reactions. Despite the potential cross-talks between SARS-CoV-2 infection and TRIM28, SETDB1, and HERVs, information on their expressions in COVID-19 patients is lacking. We assessed, through a PCR real time Taqman amplification assay, the transcription levels of six IFN-I stimulated genes, IFN-II and three of its sensitive genes, three IFN-lIIs, as well as of TRIM28, SETDB1, pol genes of HERV-H, -K, and -W families, and of env genes of Syncytin (SYN)1, SYN2, and multiple sclerosis-associated retrovirus (MRSV) in peripheral blood from COVID-19 children and in control uninfected subjects. Higher expression levels of IFN-I and IFN-II inducible genes were observed in 36 COVID-19 children with mild or moderate disease as compared to uninfected controls, whereas their concentrations decreased in 17 children with severe disease and in 11 with multisystem inflammatory syndrome (MIS-C). Similar findings were found for the expression of TRIM-28, SETDB1, and every HERV gene. Positive correlations emerged between the transcriptional levels of type I and II IFNs, TRIM28, SETDB1, and HERVs in COVID-19 patients. IFN-III expressions were comparable in each group of subjects. This preserved induction of IFN-λs could contribute to the better control of the infection in children as compared to adults, in whom IFN-III deficiency has been reported. The upregulation of IFN-I, IFN-II, TRIM28, SETDB1, and HERVs in children with mild symptoms, their declines in severe cases or with MIS-C, and the positive correlations of their transcription in SARS-CoV-2-infected children suggest that they may play important roles in conditioning the evolution of the infection.

16 March 2018 in FEMS Microbiology Ecology
Verified
Journal Article
Closed access
PDF file
GGGiorgio Gargari
Giorgio Gargari
VDValeria Deon
Valeria Deon
Valentina  TavernitiValentina Taverniti
Valentina Taverniti
CGClaudio Gardana
Claudio Gardana
MDMarco Denina
Marco Denina
Simone GuglielmettiSimone Guglielmetti
Simone Guglielmetti
Hyperlipidemia starts at a pediatric age and represents an unquestionable risk factor for cardiovascular disease. Modulation of the intestinal microbial ecosystem (IME), in principle, can ameliorate lipid profiles. In this study, we characterized the IME of children and adolescents with primary hyperlipidemia by analyzing fecal samples through 16S rRNA gene profiling (n = 15) and short chain fatty acid (SCFA) quantification (n = 32). The same analyses were also carried out on age-matched normolipidemic controls (n = 15). Moreover, we evaluated the modulatory effect of regular hazelnut intake (approximately 0.43 g of hazelnuts with skin per kg of body weight) on the IME of 15 children and adolescents with hyperlipidemia for eight weeks. We found alterations of numerous operational taxonomic units (OTUs) potentially associated with SCFA-producing bacteria and reductions in the fecal levels of acetate, butyrate and propionate in hyperlipidemic subjects. Furthermore, we observed that an eight-week hazelnut intervention may induce limited changes in fecal microbiota composition but can significantly modulate the fecal levels of predominant intestinal SCFAs, such as acetate. Finally, correlation analyses indicated that changes in lipidemic parameters are linked to modifications of the abundance of specific bacterial taxa, such as the families Lachnospiraceae and Ruminococcaceae and the genera Akkermansia, Bacteroides, Roseburia, and Faecalibacterium. This study suggests that children and adolescents with primary hyperlipidemia possess an altered IME. The promising results presented here support the need for future dietary interventions aimed at positively modulating the IME of hyperlipidemic subjects.

19 January 2023 in Viruses
Verified
Journal Article
Open access
PDF file
GPGiulia Pruccoli
Giulia Pruccoli
ECEmanuele Castagno
Emanuele Castagno
IRIrene Raffaldi
Irene Raffaldi
MDMarco Denina
Marco Denina
EBElisa Barisone
Elisa Barisone
SGSilvia Garazzino
Silvia Garazzino
The restrictive measures adopted worldwide against SARS-CoV-2 produced a drastic reduction in respiratory pathogens, including RSV, but a dramatic rebound was thereafter reported. In this multicenter retrospective observational study in 15 Pediatric Emergency Departments, all children <3 years old with RSV infection admitted between 1 September and 31 December 2021 were included and compared to those admitted in the same period of 2020 and 2019. The primary aim was to evaluate RSV epidemiology during and after the COVID-19 pandemic peak. The secondary aims were to evaluate the clinical features of children with RSV infection. Overall, 1015 children were enrolled: 100 in 2019, 3 in 2020 and 912 in 2021. In 2019, the peak was recorded in December, and in 2021, it was recorded in November. Comparing 2019 to 2021, in 2021 the median age was significantly higher and the age group 2–3 years was more affected. Admissions were significantly higher in 2021 than in 2020 and 2019, and the per-year hospitalization rate was lower in 2021 (84% vs. 93% in 2019), while the duration of admissions was similar. No difference was found in severity between 2019–2020–2021. In conclusion, after the COVID-19 pandemic, an increase in RSV cases in 2021 exceeding the median seasonal peak was detected, with the involvement of older children, while no difference was found in severity.